Publications - 'F'
Publications 676 - 700 de 1212
| Titre | DOI |
|---|---|
|
Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study N. Williet; A. Saint; A.L. Pointet; D. Tougeron; S. Pernot; A. Pozet; D. Bechade; I. Trouilloud; N. Lourenco; V. Hautefeuille; C. Locher; J. Desrame; P. Artru; A.Thirot Bidault; B. Le Roy; D. Pezet; J.M. Phelip; J. Taieb 2019 |
10.1177/1756284819878660 |
|
FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA) D. Malka; F. Castan; E. Francois; O. Bouche; J. Bennouna; F. Ghiringhelli; C. de la Fouchardiere; C. Borg; E. Samalin; J.Baptiste Bachet; J.L. Raoul; F. Cvitkovic; L. Miglianico; L. Bengrine-Lefevre; L. Dahan; C. Lecaille; T. Aparicio; H. Perrier; S. Gourgou; J. Taieb; AGEO 2015 |
10.1200/jco.2015.33.15_suppl.4013 |
|
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial D. Malka; E. Francois; F. Penault-Llorca; F. Castan; O. Bouche; J. Bennouna; F. Ghiringhelli; C. de la Fouchardiere; C. Borg; E. Samalin; J.B. Bachet; J.L. Raoul; L. Miglianico; L. Bengrine-Lefevre; L. Dahan; C. Lecaille; T. Aparicio; T. Stanbury; H. Perrier; A. Cayre; P. Laurent-Puig; S. Gourgou; J.F. Emile; J. Taieb 2019 |
10.1016/j.ejca.2019.04.020 |
|
Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial) S. Pernot; P. Artru; D. Tougeron; C. Monterymard; D. Smith; C. de la Fouchardiere; J.L. Raoul; L. Dahan; R. Guimbaud; P. Michel; J.L. Jouve; O. Pellerin; J. Taieb 2018 |
|
|
Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial) S. Pernot; P. Artru; D. Tougeron; C. Monterymard; D. Smith; C. de la Fouchardiere; J.L. Raoul; L. Dahan; R. Guimbaud; P. Michel; J.L. Jouve; O. Pellerin; J. Taieb 2018 |
|
|
Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial) S. Pernot; P. Artru; D. Tougeron; C. Monterymard; D. Smith; C. de la Fouchardiere; J.L. Raoul; L. Dahan; R. Guimbaud; P. Michel; J.L. Jouve; O. Pellerin; J. Taieb 2018 |
|
|
Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial) S. Pernot; P. Artru; D. Tougeron; C. Monterymard; D. Smith; C. de la Fouchardiere; J.L. Raoul; L. Dahan; R. Guimbaud; P. Michel; J.L. Jouve; O. Pellerin; J. Taieb 2018 |
|
|
FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study A. Zaanan; I. Trouilloud; T. Markoutsaki; M. Gauthier; A.C. Dupont-Gossart; T. Lecomte; T. Aparicio; P. Artru; A. Thirot-Bidault; F. Joubert; D. Fanica; J. Taieb 2014 |
10.1186/1471-2407-14-441 |
|
FOLFOX-aflibercept followed by maintenance therapy with fluoropyrimidine-aflibercept as first-line therapy in patients with metastatic colorectal cancer: A GERCOR single-arm phase II study (VELVET) B. Chibaudel; T. Andre; J.Baptiste Bachet; D. Auby; J. Desrame; G. Deplanque; C. Lecaille; C. Louvet; C. Tournigand; V. Lebrun-Ly; J. Dauba; G. Lledo; M.Line Garcia; N.Baba Hamed; M. Wagner; M. Attia; A. Meurisse; A. Tijeras-Raballand; F. Bonnetain; A. de Gramont; GERCOR 2015 |
10.1200/jco.2015.33.15_suppl.3567 |
|
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized M. Hebbar; B. Chibaudel; T. Andre; L. Mineur; D. Smith; C. Louvet; J.L. Dutel; M. Ychou; J.L. Legoux; M. Mabro; R. Faroux; D. Auby; D. Brusquant; A. Khalil; S. Truant; A. Hadengue; C. Dalban; B. Gayet; F. Paye; F.R. Pruvot; F. Bonnetain; J. Taieb; P. Brucker; B. Landi; M. Flesch; E. Carola; P. Martin; E. Vaillant; A. de Gramont; G.Cooperateu Multidisciplinaire 2015 |
10.1093/annonc/mdu539 |
|
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized M. Hebbar; B. Chibaudel; T. Andre; L. Mineur; D. Smith; C. Louvet; J.L. Dutel; M. Ychou; J.L. Legoux; M. Mabro; R. Faroux; D. Auby; D. Brusquant; A. Khalil; S. Truant; A. Hadengue; C. Dalban; B. Gayet; F. Paye; F.R. Pruvot; F. Bonnetain; A. de Gramont; G.Cooperateu Multidisciplinaire 2015 |
10.1093/annonc/mdv141 |
|
FOLFOXIRI versus FOLFIRINOX in first-line chemotherapy in patients with advanced pancreatic cancer: A propensity score analysis A. Vienot; H. Chevalier; C. Bolognini; E. Gherga; A. Meurisse; D. Vernerey; C. Borg; A. Turpin 2019 |
|
|
FOLFOXIRI versus FOLFIRINOX in first-line chemotherapy in patients with advanced pancreatic cancer: A propensity score analysis A. Vienot; H. Chevalier; C. Bolognini; E. Gherga; A. Meurisse; D. Vernerey; C. Borg; A. Turpin 2019 |
|
|
FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study A. Vienot; H. Chevalier; C. Bolognini; E. Gherga; E. Klajer; A. Meurisse; M. Jary; S. Kim; C. d'Engremont; T. Nguyen; F. Calcagno; H. Almotlak; F. Fein; M. Nasri; S. Abdeljaoued; A. Turpin; C. Borg; D. Vernerey 2020 |
10.4251/wjgo.v12.i3.332 |
|
Foliated hyperbolicity and foliations with hyperbolic leaves C. Bonatti; X. Gomez-Mont; M. Martinez 2020 |
10.1017/etds.2018.61 |
|
Foliations making a constant angle with principal directions on ellipsoids R. Garcia; R. Langevin; P. Walczak 2015 |
10.4064/ap113-2-4 |
|
Follicular dendritic cell sarcoma in head and neck region T. Cerda; X.S. Sun; A. Cazorla; C. Laurent; F. Floret; J. Haudebourg; A. Thyss; J. Thariat 2014 |
10.1016/j.canrad.2013.10.010 |
|
Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy J. Niogret; H. Berger; C. Rebe; R. Mary; E. Ballot; C. Truntzer; M. Thibaudin; V. Derangere; C. Hibos; L. Hampe; D. Rageot; T. Accogli; P. Joubert; B. Routy; J. Harker; F. Vegran; F. Ghiringhelli; F. Chalmin 2021 |
10.1136/jitc-2020-002157 |
|
Follicular Lymphoma of Breast T. Terada 2016 |
10.1111/tbj.12580 |
|
Follow-up of a French national cohort of melanoma stage IV and unresectable stage III patients, MelBase. C. Allayous; S. Dalle; P. Saiag; C. Dutriaux; L. Mortier; A. Dupuy; T. Lesimple; P. Bahadoran; S. Dalac; M. -Beylot-Barry; E. Maubec; P.E. Stoebner; F. Aubin; J.P. Arnault; L. Verneuil; B. Dreno; A. Kowal; R. Porcher; M.Therese Leccia; C. Lebbe 2015 |
|
|
Follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society for Vascular Surgery M. Venermo; M. Sprynger; I. Desormais; M. Bjorck; M. Brodmann; T. Cohnert; M. De Carlo; C. Espinola-Klein; S. Kownator; L. Mazzolai; R. Naylor; C. Vlachopoulos; J.B. Ricco; V. Aboyans 2019 |
10.1177/2047487319846999 |
|
Follow-up of patients with complete remission of locally advanced basal cell carcinoma treated with vismodegib after treatment discontinuation: A retrospective multicentric French study. F. Herms; L. Haudebourg; M. Bagot; C. Dutriaux; J.Jacques Grob; B. Guillot; G. Jeudy; J. Lambert; C. Lebbe; C. Mateus; N. Meyer; S. Monestier; L. Mortier; N. Poulalhon; S. Prey; C. Robert; P. Vabres; M. Mouri; N. Basset-Seguin 2017 |
10.1200/JCO.2017.35.15_suppl.9535 |
|
Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study J. Viot; M. Bachour; A. Meurisse; X. Pivot; F. Fiteni 2017 |
10.1016/j.breast.2017.05.005 |
|
Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react C. Pochon; E. Oger; G. Michel; J.H. Dalle; A. Salmon; B. Nelken; Y. Bertrand; H. Cave; J.M. Cayuela; N. Grardel; E. Macintyre; G. Margueritte; F. Mechinaud; P. Rohrlich; C. Paillard; F. Demeocq; P. Schneider; D. Plantaz; M. Poiree; J.F. Eliaou; G. Semana; S. Drunat; P. Jonveaux; P. Bordigoni; V. Gandemer 2015 |
10.1111/bjh.13272 |
|
Follow-up tricuspid annular plane systolic excursion predicts survival in pulmonary arterial hypertension J.A. Mazurek; A. Vaidya; S.C. Mathai; J.D. Roberts; P.R. Forfia 2017 |
10.1177/2045893217694175 |